Quarterly results jar Halozyme Therapeutics (HALO) shareholders

Halozyme Therapeutics (HALO) recently reported quarterly results, with revenue up 51.6% year on year and slightly ahead of expectations. However, EPS missed estimates, and full-year EPS guidance came in below analyst forecasts, weighing on sentiment.

At a share price of $63.29, Halozyme Therapeutics has seen momentum ease recently, with a 30 day share price return of a 10.05% decline contrasting with a 3 year total shareholder return of 69.63%.

If this earnings driven pullback has you rethinking your watchlist, it could be a good time to size up other healthcare names using our screener of 36 healthcare AI stocks

With Halozyme trading below analyst price targets and recent results showing strong revenue but softer EPS, you need to decide whether the market is overlooking the long term earnings potential here or already pricing in future growth.

Most Popular Narrative: 25.1% Undervalued

Halozyme's most followed narrative tags a fair value of $84.50 per share, which sits well above the last close at $63.29, so the gap between price and story is clear.

The accelerating adoption of subcutaneous drug delivery in place of traditional intravenous administration, evidenced by rapid conversion rates (e.g., DARZALEX subcutaneous now 96% in the US) and label expansions (Phesgo for at-home administration), positions Halozyme's ENHANZE platform as a core beneficiary of the global shift towards more patient-friendly, convenient, and cost-effective treatment modalities. This structural shift is expected to support continued robust growth in royalty revenues and net margin expansion over the long term.

Curious what supports that higher fair value? The narrative leans on a specific path for royalty growth, margin expansion and future earnings power, built from detailed analyst assumptions.

Result: Fair Value of $84.50 (UNDERVALUED)

However, this narrative can unwind quickly if patent challenges succeed or if key royalty partners, such as DARZALEX or Phesgo, lose momentum or face tougher reimbursement.

Another angle on valuation

Analysts see Halozyme as 25.1% undervalued at $63.29 based on future cash flows, yet the current P/E of 23.7x is higher than both the peer average of 20.1x and a fair ratio of 20.1x. That premium can signal extra risk if growth or margins fall short, so which signal matters more to you?

Next Steps

With mixed signals on valuation and sentiment running both hot and cold, it helps to move quickly and stress test the details yourself using 3 key rewards and 4 important warning signs.

Looking for more investment ideas?

If Halozyme has sharpened your focus, do not stop here. Broaden your opportunity set now by checking stocks that balance quality, income and potential mispricing.

• Target quality at a discount by searching for companies that look mispriced on fundamentals with our 61 high quality undervalued stocks.
• Strengthen your income stream by reviewing yield heavy candidates highlighted in the 12 dividend fortresses.
• Prioritise resilience by scanning for companies with stronger finances using the solid balance sheet and fundamentals stocks screener (39 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.